Working with TipRanks
Follow Us
Research Tools
Calendars
Calculators
Education
About Us
Working with TipRanks
Follow Us
Adamas Pharmaceuticals (ADMS)
NASDAQ:ADMS
Adamas Pharmaceuticals (ADMS) Stock Price & Analysis
0 Followers
ADMS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$4.02 - $9.15
Previous Close$8.22
VolumeN/A
Average Volume (3M)951.98K
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)-4.8
Beta2.81
Next EarningsN/A
EPS Estimate
-1.7Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.70
Shares OutstandingN/A
10 Day Avg. Volume964,775
30 Day Avg. Volume1,146,939
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$8.40Price Target Upside2.19% Upside
Rating ConsensusHold
Number of Analyst Covering7
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Product Insights
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ADMS FAQ
What was Adamas Pharmaceuticals’s price range in the past 12 months?
Adamas Pharmaceuticals lowest stock price was $4.02 and its highest was $9.15 in the past 12 months.
What is Adamas Pharmaceuticals’s market cap?
Adamas Pharmaceuticals’s market cap is 376.37M.
When is Adamas Pharmaceuticals’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Adamas Pharmaceuticals’s earnings last quarter?
Currently, no data Available
Is Adamas Pharmaceuticals overvalued?
According to Wall Street analysts Adamas Pharmaceuticals’s price is currently Undervalued.
Does Adamas Pharmaceuticals pay dividends?
Adamas Pharmaceuticals does not currently pay dividends.
What is Adamas Pharmaceuticals’s EPS estimate?
Adamas Pharmaceuticals’s EPS estimate is -1.7.
How many shares outstanding does Adamas Pharmaceuticals have?
Adamas Pharmaceuticals has 45,790,000 shares outstanding.
What happened to Adamas Pharmaceuticals’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Adamas Pharmaceuticals?
Among the largest hedge funds holding Adamas Pharmaceuticals’s share is Fisher Asset Management LLC. It holds Adamas Pharmaceuticals’s shares valued at N/A.
---
Adamas Pharmaceuticals Stock Smart Score
Learn more about TipRanks Smart Score
Company Description
Adamas Pharmaceuticals
Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA.
---
Forecast EPS vs Actual EPS
Currently, no data available
Please return soon. This page is being updated.
---